Intrahepatic Cholangiocarcinoma — Trials

Intrahepatic Cholangiocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 88
Recruiting: 53
Ph III recruiting: 2
Growth YoY: +23.8%
Industry share: 9%
Top sponsor: Fudan University
Termination share: 47.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (31)

clinicaltrialsPublishedShowing 201–227 of 227 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01347333	Stereotactic Body Radiotherapy for Liver Tumors	completed	N/A	23	Mercy ResearchOTHER	1	Mar 3, 2020	clinicaltrials
NCT03267940	Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma	terminated	Phase 1	85	Halozyme TherapeuticsINDUSTRY	3	Feb 7, 2020